Vyant Bio, Inc.

Thank you for standing by, and welcome to the ViantBio Second Quarter 2022 Earnings Conference Call and Webcast. Today, August 22, 2022, the company issued a press release summarizing the results for the second quarter of 2022. Today's discussion will provide an overview of activities in the second quarter and first half of 2022. The presentation will be followed by a question-and-answer session. At this time, I'd like to turn the conference over to Jay Roberts, Chief Executive Officer of ViantBio. Please go ahead, sir.

Thank you, operator, and thank you all for joining us today. We spent the first half of 2022 fully focused on progressing our scientific research and development business plan and working through the divestiture of our preclinical CRO services business, MevoPharm. We're delighted to speak with you today to share our enthusiasm to give you some insight into how we envision the near-term future of Buy and Bio while providing our financial results for the second quarter and first half of 2022. As such, on the call with me today is Buy and Bio's Chief Financial Officer, Andy LaFrance, and our Chief Scientific Officer, Dr. Robert Fermot. Following the Safe Harbor Statement, I will start out with a brief overview of Buy and Bio and describe the corporate initiatives we have accomplished so far this year. And Dr. Fermot will provide an overview and update on recent scientific achievements made in the first half of the year and the vision ahead. And finally, many of our friends will take us through a brief financial update and discuss key accounting matters for the second quarter and first half of 2022. I will make some closing remarks, and then we will go to questions. And I'll turn the call over to our CFO, Andy LaFrance.

Thank you, Jay, and welcome to all. We'd like to remind everyone that various comments about future expectations, plans, prospects constitute forward-looking statements for purposes of safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Bio cautions that these forward-looking statements are subject to risks and uncertainties that may cause or actual results to differ materially from those indicated including risks described in the company's filings with the Securities and Exchange Commission. Any forward-looking statements made on this conference call speak only as of today's date, Monday, August 22, 2022, and ViantBio does not intend to update any of these forward-looking statements to reflect the events or circumstances that would occur at today's date. This conference call is also being recorded for audio rebroadcast on ViantBio's website, at www.VyandBio.com. With that, I would like to turn the call back over to Jay Roberts. Jay?